-
Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response Enrique Colado; Teresa Paíno Gómez; Patricia Maiso; Enrique M Ocio San Miguel; Xi Chen Chen; Stela Álvarez Fernández; Norma Carmen Gutiérrez Gutiérrez; Jesus Martin-Sanchez; Juan Alejandro Flores Montero; Laura San Segundo Payo; Mercedes Garayoa Berrueta; Diego Fernández Lázaro; María Belén Vidriales Vicente; Carlos M. Galmarini; Pablo Aviles; Carmen Cuevas; Atanasio Pandiella ; Jesús Fernando San Miguel Izquierdo Haematologica-The Hematology Journal 96: 687-695. FI: 6,532(Q1)
-
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial Mateos MV, Oriol A, Martínez-López J, Gutiérrez N, Teruel AI, de Paz R, García-Laraña J, Bengoechea E, Martín A, Mediavilla JD, Palomera L, de Arriba F, González Y, Hernández JM, Sureda A, Bello JL, Bargay J, Peñalver FJ, Ribera JM, Martín-Mateos ML, García-Sanz R, Cibeira MT, Ramos ML, Vidriales MB, Paíva B, Montalbán MA, Lahuerta JJ, Bladé J, San Miguel JF. Lancet Oncology 11(10):934-41. FI: 14.470 (Q1) Bortezomib plus melphalan and prednisone compared with melpahaln and prednisone in previously untreated multiple myeloma updated follow-up and impact of subsequent therapy in the phase III VISTA trial Mateos MV, Richardson PG, Schlag R, Khuageva NK, Dimopoulos MA, Shpilbereg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Esseltine DL, Liu K, Cakana A, van de Velde H, San Miguel JF. Journal of Clinical Oncology 28(13):2259-66. FI: 17.793 (Q1) Circulating human B and plasma cells. Age-associated changes in counts and detailed characterization of circulating normal CD138-and CD138 plasma cells Caraux A, Klein B, Paíva B, Bret C, Schmitz A, Fuhler GM, Bos NA, Johnsen HE, Orfao A, Perez-Andres M. Haematologica 95(6):1016-20. FI: 6.416 (Q1) Concluding remarks and future directions in myeloma San Miguel JF. Blood Reviews 24 Suppl 1:S33-4. FI: 7.185 (Q1) Current multiple myeloma treatment strategies with novel agents: a European perspective Ludwig H, Beksac M, Bladé J, Boccadoro M, Cavenagh J, Cavo M, Dimopoulos M, Drach J, Einsele H, Facon T, Goldschmidt H, Harousseau JL, Hess U, Ketterer N, Kropff M, Mendeleeva L, Morgar G, Palumbo A, Plesner T, San Miguel JF, Shpilberg O, Sondergeld P, Sonneveld P, Zweegman S. Oncologist 15(1):6-25. FI: 6.701 (Q1) Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling Gutiérrez NC, Sarasquete ME, Misiewicz-Krzeminska I, Delgado M, de la Rivas J, Ticona FV, Fermiñan E, Martín-Jiménez P, Chillón C, Risueño A, Hernández JM, García Sanz R, González M, San Miguel JF. Leukemia 24(3):629-37. FI: 8.296 (Q1) Grupo Español de MM and Programa para el Estudio de la Terapéutica en Hemopatía Maligna Cooperative Study Groups. Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study Lahuerta JJ, Mateos MV, Martínez-López J, Grande C, De La Rubia J, Rosinol L, Sureda A, García-Laraña J, Díaz-Mediavilla J, Hernández-García MT, Carrera D, Besalduch J, de Arriba F, Oriol A, Escoda L, García-Frade J, Rivas-González C, Alegre A, Bladé J, San Miguel JF. Haematologica 95(11):1913-20. FI: 6.416 (Q1) Guidelines for the use of bisphosphonates in multiple myeloma: recommendations of the expert committee of the Spanish myeloma group from the PETHEMA group García-Sanz R, Alegre A, Capote FJ, Hernández JM, Rosiñol L, Rubia JD, Sureda A, Arriba FD, Bargay J, Díaz-Mediavilla J, García-Larña J, Lahuerta JJ, Mateos MV, Prósper F, San Miguel JF, Bladé J. Medicina Clínica 134(6):268-78. FI: 1.231 (Q3) In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma Ocio EM, Vilanova D, Atadja P, Maiso P, Crusoe E, Fernández-Lázaro D, Garayoa M, San-Segundo L, Hernández-Iglesias T, de Álava E, Shao W, Yao YM, Pandiella A, San Miguel JF. Haematologica 95(5):794-803. FI: 6.416 (Q1)
|
